Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Novavax's change in inventory for the quarter that ended in Jun. 2026 was CHF-0.3 Mil. It means Novavax's inventory
increased by CHF0.3 Mil
from Mar. 2026 to Jun. 2026 .
Novavax's change in inventory for the fiscal year that ended in Dec. 2025 was CHF-2.6 Mil. It means Novavax's inventory
increased by CHF2.6 Mil
from Dec. 2024 to Dec. 2025 .
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Novavax's Days Inventory for the quarter that ended in Jun. 2026 was 68.19.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Novavax's Inventory Turnover for the quarter that ended in Jun. 2026 was 1.34.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Novavax's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 0.19.
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Novavax's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novavax Change In Inventory Related Terms
Novavax Change In Inventory Historical Data
* Premium members only.
The historical data trend for Novavax's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-1.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Inventory of CHF-1.7 Mil mean?
Novavax (XSWX:NVAX) has a Change In Inventory of CHF-1.7 Mil as of Jun. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Novavax and its competitors.
Is Novavax's Change In Inventory too high?
Novavax's current Change In Inventory is CHF-1.7 Mil. Overall, Novavax has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Novavax's Change In Inventory compare to JBIO and AVLN?
Novavax's Change In Inventory of CHF-1.7 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Biotechnology company?
A good Change In Inventory depends on the Biotechnology industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Novavax and its competitors. Novavax's current Change In Inventory is CHF-1.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novavax stock overvalued right now?
Novavax (XSWX:NVAX) has a current Change In Inventory of CHF-1.7 Mil. The stock's GF Value™ is CHF2.58, compared to a current price of CHF7.24 — trading 180.7% above its estimated fair value. The current Change In Inventory is CHF-1.7 Mil. Novavax's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Novavax (XSWX:NVAX), the current Change In Inventory is CHF-1.7 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novavax (XSWX:NVAX) Overvalued in 2026?
Based on GuruFocus' analysis, Novavax stock appears to be overvalued.
The current stock price of CHF7.24 is trading 180.7% above its estimated GF Value™ of CHF2.58.
Key valuation signals for XSWX:NVAX:
Change In Inventory: CHF-1.7 Mil
GF Value™: CHF2.58 vs. price of CHF7.24 (180.7% above fair value)
No single metric tells the full story. See the XSWX:NVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
46GF Score
Get the complete analysis for XSWX:NVAX
Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:NVAX has been successfully added to your 
